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Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent
oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients
with hepatic colorectal metastasis
Aims: Because of its efficacy, oxaliplatin (OX) is
increasingly used as a chemotherapeutic agent in the
treatment of colorectal liver metastases (CRLM). Oxa-
liplatin-associated liver toxicity has been reported and
can affect clinical practice, but studies on its prevalence
and a full pathological description are lacking. The
aims of this study were to fill this gap by providing,
from a pathologist’s perspective, a detailed assessment
of the spectrum of hepatic lesions associated with OX,
to suggest a scoring system to quantify them, and to
investigate the protective effect of bevacizumab against
OX-associated damage.
Methods and results: The spectrum of oxaliplatin-asso-
ciated liver lesions was investigated in a multi-institu-
tional series of surgically resected CRLM (n = 385).
Among 274 patients treated by OX, 54% had moder-
ate ⁄ severe sinusoidal obstruction syndrome (SOS).
Peliosis, centrilobular perisinusoidal ⁄ venular fibrosis
and nodular regenerative hyperplasia (NRH) developed
in 10.6%, 47% and 24.5%, respectively. The 111
patients treated by surgery alone had no lesions.
Hepatic lesions were less severe in patients treated
with OX ⁄ bevacizumab (n = 70) compared with the
group treated by OX alone (n = 204), with an inci-
dence of moderate ⁄ severe SOS (31.4% versus 62.2%),
peliosis (4.3% versus 14.6%), NRH (11.4% versus
28.9%, respectively) and centrilobular ⁄ venular fibrosis
(31.4% versus 52%, respectively) (P < 0.001).
Conclusions: Pathologists should be aware of the dis-
tinctive lesions associated with OX and of their high
prevalence. OX-related lesions are less frequent in
patients treated with bevacizumab, suggesting that this
drug has a preventive effect. Uniform criteria for
diagnosis and grading of OX-associated lesions should
help to include histological data in the optimal multi-
disciplinary management of CRLM.
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Introduction
Until recently, the role of the pathologist in surgery for
colorectal liver metastases (CRLM) was limited to
checking the margins of the resection and, when
hepatic lesions were synchronous to primary tumour,
to establishing the TNM grade of the disease. Today,
the pathologist can give information to the surgeon
and oncologist on the degree of histological response of
the CRLM to preoperative chemotherapy and draw
attention to the distinctive toxic hepatic lesions asso-
ciated with chemotherapy, both major determinants in
management and outcome.
In fact, chemotherapy of CRLM has dramatically
improved over the last decade, with tumour response
rates increasing from 25% with 5-fluorouracil (5-FU) to
up to 80% using different combinations of new
chemotherapeutic agents such as oxaliplatin (OX) and
irinotecan, and recently with biological agents such as
bevacizumab [an antibody against vascular endothelial
growth factor-A (VEGF-A)] and cetuximab (an anti-
body against epithelial growth factor-receptor). Such
effective chemotherapies are increasingly used before
hepatic surgery to render unresectable CRLM resect-
able,1–7 as neoadjuvant treatment, and in innovative
strategies for patients with advanced synchronous
colorectal and hepatic disease.8–10 The results are an
increased number of patients qualifying for curative
surgical procedures, and improved overall patient
survival.
As a side-effect, chemotherapeutic damage to the
non-neoplastic liver is increasingly observed, particu-
larly in association with OX. Since our initial report,11
several single-institution series have confirmed the
presence of hepatic adverse effects of OX, and their
relevance to perioperative management and postoper-
ative outcomes.12–16 Although a more cautious
approach to the use of preoperative chemotherapy
has been recommended,17,18 and surgical strategies
such as portal vein embolization and two-step hepa-
tectomies are implemented considering OX-related liver
damage,10 a larger investigation on the prevalence and
severity of hepatic lesions is lacking.
Patients, materials and methods
patients
The pathological material and clinical data of 385
patients who had undergone liver resection for CRLM
at Geneva University Hospital (Geneva, Switzerland)
(n = 157), at Hoˆpital Cochin (Paris, France) (n = 137),
at Massachusetts General Hospital (Boston, MA, USA)
(n = 66) and at MD Anderson Cancer Center (Houston
TX, USA) (n = 25) was reviewed. Patient inclusion
criteria were absence of underlying chronic liver
disease (serologically confirmed), absence of cardiopul-
monary diseases and >20 mm of non-neoplastic liver
tissue available for morphological evaluation. Systemic
chemotherapy had been given before hepatic surgery in
274 cases. Surgical resection had been the only
treatment for the metastases in 111 cases (control
group). Two hundred and four patients received OX ⁄ 5-
FU)-based chemotherapy and 70 received OX ⁄ 5-FU in
association with bevacizumab. Irinotecan was added to
OX in 79 patients (OX combined with irinotecan and
5-fluorouracil ⁄ leucovorin therapy7). The study was
performed in accordance with ethical standards of the
Helsinki Declaration of the World Medical Association.
The group included 219 men and 166 women. The
mean age was 63 years (range 36–82 years). The liver
resection specimens included 199 right hepatectomies,
89 left hepatectomies and 97 segmental resections.
Vascular exclusion (Pringles’ manoeuvre or total vas-
cular exclusion) was performed during surgery in 45
cases. Preoperative portal vein embolization was per-
formed in 89 cases in order to increase the volume of
the future liver remnant.
tissues
Archival material (prepared from formalin-fixed para-
ffin-embedded tissue) was reviewed for all patients, and
representative sections of non-neoplastic hepatic paren-
chyma >20 mm distant from the tumour were selected
for categorization and quantification of the lesions.
Morphological analysis was based in all cases on
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haematoxylin and eosin (H&E), Masson trichrome and
reticulin stains. To ensure consistency, the review of
the entire series of histopathological material was
performed by the lead author (L.R-B.), at multiheaded
microscopic sessions with each of the other participat-
ing pathologists (G.Y.L., H.W., and B.T.). At the time of
the histopathological review the pathologists were
unaware of the patients’ clinical data, including the
preoperative chemotherapy.
Histological features reflecting parenchymal, stro-
mal and vascular changes were evaluated (Table 1).
Among these, sinusoidal dilation, nodular regenera-
tion, centrilobular or portal vein lesions, centrilobular
vein and perisinusoidal fibrosis and steatosis were
graded categorically as follows: for sinusoidal dilation:
0, absent; 1, mild (centrilobular involvement limited
to one-third of the lobular area); 2, moderate (centri-
lobular involvement extending in two-thirds of the
lobular area); 3, severe (complete lobular involvement
or centrilobular involvement extending to adjacent
lobules with bridging congestion); for nodular regen-
eration according to Wanless19,20 as follows: 0,
absent; 1, mild (focal occasionally distinct nodular
hyperplasia on reticulin staining but indistinct on
H&E staining); 2, moderate (focal distinct nodular
hyperplasia apparent on H&E staining, clearly high-
lighted on reticulin staining); 3, severe [diffuse nod-
ular hyperplasia, distinct in most areas on H&E
staining and highlighted on reticulin staining, corre-
sponding to nodular regenerative hyperplasia (NRH)];
for centrilobular or portal vein lesions and centrilob-
ular perisinusoidal and vein fibrosis as follows: 0,
absent; 1, mild (<50% of veins and sinusoids evalu-
ated on 20 fields at ·200 magnification); 2, moderate
(>50% of veins and sinusoids evaluated on 20 fields
at ·200 magnification). The area of a single high-
power field is 0.315 mm2. Steatosis was estimated as
the percentage of involved hepatocytes and catego-
rized as follows: 0, absent; 1, mild (steatosis 10–30%
of the hepatocytes); 2, moderate (steatosis in 30–60%
of the hepatocytes); 3, severe (steatosis in >60% of
the hepatocytes). Peliosis, perisinusoidal haemorrhage
and hepatocellular changes were evaluated as present
or absent.
The v2 test was used to correlate the different groups
of patients according to the presence or absence of
preoperative treatment and type of chemotherapy
versus the presence of OX-associated lesions. P-values
were considered statistically significant if <0.05.
Results
pathological les ions of non-neoplsatic l iver
after preoperative chemotherapy
Among the 274 hepatic resections for CRLM treated
with preoperative OX-based chemotherapy, 204
(74.4%) showed lesions in the non-neoplastic hepatic
parenchyma.
s inusoidal dilation and sinusoidal
obstruction syndrome
Low-power microscopic examination revealed distinct
bands of sinusoidal congestion (Figure 1A) that pre-
dominated in centrilobular zones and were character-
ized by sinusoidal dilation filled with plugs of
erythrocytes. In grade 2 and 3 sinusoidal dilation,
perisinusoidal haemorrhage characterized by erythro-
cyte extravasation in the perisinusoidal space
(Figure 1B) was present, consistent with rupture of
sinusoidal wall integrity as observed in sinusoidal
obstruction syndrome (SOS) lesions.11,21 The erythro-
cytic extravasation was either focal or diffuse along
the dilated sinusoid. Occasionally, the vascular dila-
tion involved venular inlets, which then became
easily discernible. Areas of sinusoidal dilation were
variably accompanied by atrophy of hepatocellular
plates or by hepatocytic dissociation. Hepatocellular
necrosis was rare. Although lesions were predomi-
nantly visible in the subcapsular region, they were
Table 1. Evaluated histological features
Parenchymal lesions
Sinusoidal dilation (grade 0, 1, 2, 3)
Perisinusoidal haemorrhage
Peliosis
Nodularity (including nodular regenerative hyperplasia)
(grade 0, 1, 2, 3)
Steatosis (grade 0, 1, 2, 3)
Steatohepatitis
Hepatocellular damage (necrosis, apoptosis, atrophy)
Venular lesions
Centrilobular vein or portal vein lesions (endothelial cell
rounding) (grade 0, 1, 2)
Fibrosis
Perisinusoidal fibrosis (grade 0, 1, 2)
Centrilobular vein fibrosis (grade 0, 1, 2)
Portal vein fibrosis (grade 0, 1, 2)
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haphazardly distributed with affected lobules inter-
mingled with intact parenchyma. Among the 274
hepatic resections, the severity of sinusoidal dilation
was grade 0 in 26%, grade 1 in 19.7%, grade 2 in
22.6% and grade 3 in 31.7%. In severe cases,
microscopic sinusoidal congestion appeared macro-
scopically as the typical bluish-red marbled feature
(Figure 2).
In 29 of 274 patients (10.6%), sinusoidal dilation
exhibited a large haemorrhagic pattern, representing
peliosis (Figure 3), some measuring up to several
millimetres often macroscopically discernible. Peliosis
was present in 30% of patients with grade 3 sinusoidal
dilation, but in only 1% of patients with grade 2 or
grade 1 sinusoidal dilation, and was never found in
patients without sinusoidal dilation.
veins and centrilobular fibrosis
In 129 of 274 (47%) patients, centrilobular veins
occasionally showed focal endothelial cell rounding
and ⁄ or intimal haemorrhage. Grade 0, grade 1 and
grade 2 were observed in 53, 40.5 and 6.5%, respec-
tively. Notably, endothelial lesions were never observed
in portal veins. Centrilobular vein injury was focally
present in 86% of patients with grade 3 sinusoidal
dilation, 64.5% of patients with grade 2 sinusoidal
dilation and 26% with grade 1 sinusoidal dilation and
never in patients without sinusoidal dilation.
Centrilobular fibrosis was observed in 128 of 274
(46.7%) patients. Depending on the zone within the
same patient, it concerned mainly the centrilobular
veins and ⁄ or sinusoids. It resulted in variable degrees
of luminal occlusion (Figure 4A), only rarely complete.
A
B
Figure 1. A, Low-power examination on Trichrome Masson stain
of the liver reveals areas of sinusoidal congestion involving centri-
lobular and mediolobular lobular areas. The small hepatic vein is
not occluded by fibrous tissue. B, At high-power examination,
sinusoidal congestion is severe, outlined by atrophic hepatocyte
trabeculae. The perisinusoidal space of Disse (arrow) is extensively
dilated and contains several erythrocytes in close contact with
hepatocytes.
Figure 2. Macrosopically, on the cut surface, the liver is diffusely
nodular. Nodules are outlined by congested areas.
Figure 3. High-power examination on reticulin stain, sinusoidal
dilation exhibits a cystic-like pattern, representing peliosis.
Oxaliplatin-sinusoidal lesions frequent, partially prevented by bevacizumab 433
 2010 The Authors. Journal compilation  2010 Blackwell Publishing Ltd, Histopathology, 56, 430–439.
Centrilobular perisinusoidal fibrosis was often segmen-
tal (Figure 4B,C). No extensive fibrosis or fibrotic septa
were observed. Amongst 274 patients, grade 0, grade 1
and grade 2 centrilobular fibrosis was observed in 53.4,
33.9 and 12.7%, respectively. Mild centrilobular fibro-
sis was present in 81.6% of patients with grade 3
sinusoidal dilation, in 61.3% of those with grade 2 and
31.5% of those grade 1 and never in patients without
sinusoidal dilation.
nodular transformation
Nodular transformation was observed in 158 (57.7%)
of 274 patients. Nodular transformation corresponded
to the development of small bulging nodules composed
of enlarged hepatocytic cells occasionally centred
around portal tracts and delineated at the periphery
by atrophic hepatocytes or by dilated sinusoids.
Amongst 274 patients, grade 0, grade 1, grade 2 and
grade 3 (i.e. NRH) lesions (Figure 5) were observed in
42.3, 17.9, 15.3 and 24.5%, respectively. Grade 3
nodular transformation ⁄ NRH was present in 59.8%
of patients with grade 3 sinusoidal dilation, in 19.3%
of those with grade 2 sinusoidal dilation and 5.5% of
patients with grade 1 sinusoidal dilation. Nodular
transformation was not observed in any of 71 patients
without sinusoidal dilation.
steatosis
Steatosis was present in 109 of the 274 patients
(39.8%). It was grade 1, grade 2 and grade 3 in 60%,
29% and 11%, respectively. Steatohepatitis was absent
in our series. There was no correlation between the
presence of steatosis and the presence of sinusoidal
dilation.
No correlation was observed between preoperative
portal vein embolization or ligation or perioperative
A
B
C
Figure 4. A, High-power examination on Trichrome Masson stain
of the liver small hepatic vein is partially occluded by fibrous tissue.
B, On high-power examination on Trichrome Masson stain, fibrosis is
present focally or (C) diffusely along centrilobular sinusoids.
Figure 5. Low-power examination on reticulin stain shows a regen-
erative nodule made of enlarged hepatocytic cells centred by portal
tracts and delineated at the periphery by atrophic hepatocytes.
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vascular exclusion and any of the above-mentioned
chemotherapy-associated changes (P > 0.05).
pathological les ions of non-neoplastic liver
treated by surgery alone
Of 111 patients with CRLM treated by surgery alone,
steatosis was present in 37%. The prevalence of
steatosis was not significantly different from that of
patients having received neoadjuvant chemotherapy
(39.8%). Other types of lesions were not found.
distribution of chemotherapy-associated
changes according to age and gender
The prevalence and type of chemotherapy-associated
changes was the same in men and women and was not
related to age (P > 0.05).
correlation of histological les ions
according to the type of chemotherapy
The pathological characteristics of patients treated
before surgery by OX with or without bevacizumab
and patients treated by surgery alone are shown in
Table 2. The prevalence of hepatic lesions was signif-
icantly lower in the group treated with OX with
bevacizumab (45 of 70 patients; 64.3%) compared
with the group treated by OX without bevacizumab
(158 of 204 patients; 77.4%) (P < 0.05). The severity
of the changes was also less, with a decreased ratio of
moderate to severe sinusoidal dilation (31.4% versus
62.2%; P < 0.05), of peliosis (4.3% versus 14.6%), of
NRH (11.4% versus 28.9%), and of centrilobular ⁄ ven-
ular fibrosis (31.4% versus 52%), respectively
(P < 0.001). In contrast, the prevalence of steatosis
was similar between the three groups. Steatosis was not
correlated with irinotecan use.
Discussion
This study has established the prevalence of OX-related
liver damage, provided a detailed pathological descrip-
tion and grading of these changes serving as a common
language in the multidisciplinary team managing
CRLM patients, and demonstrated the partial protective
effect of bevacizumab on each type of lesion.
prevalence of ox-related damage
One of the main findings of the present study is the
high prevalence of moderate to severe sinusoidal
lesions in patients receiving OX (54%). The chemo-
therapy regimens given were similar, if not identical,
between the four participating centres in terms of
duration, dose and number of cycles. Nevertheless, the
spectrum of pathological changes observed was iden-
tical in specimens in all four participating centres, the
prevalence of changes, i.e. SOS, were in the same range
in each given centre compared with the others, and
matched our previous reports.11 Differences in preva-
lence from other published groups12 may be explained
by (i) a more homogeneous population in our study as
regards chemotherapy (only patients receiving oxali-
platin-based regimen were included) and type of
administration received, although differences from
other centres may be found in the number of cycles
of chemotherapy, in the type of OX-based regimen, or
in the combination of several chemotherapeutic proto-
cols, as recently reported by Nakano et al.14; (ii) under-
recognition: lesions being overlooked in centres that do
not systematically perform special staining such as
reticulin or do not focus on the non-neoplastic liver,
e.g. with large sampling that follows otherwise rela-
tively standardized protocols of chemotherapy13; (iii)
the fact that some studies report the prevalence of
grade 2 or 3 SOS lesion only, whereas we reported the
prevalence of grade 1 (19.7% of cases in the actual
series), 2 and 3; (iv) the absence of a full consensus
between pathologists on the definition of sinusoidal
lesions related to chemotherapy.
Irinotecan associated with OX has no effect on
severity of SOS lesions, and 5-FU alone is not respon-
sible for grade 2 and 3 SOS lesions.11–14,22
detailed description and continuum of
ox-related damage
Our study has shown that toxic liver injury to
sinusoidal endothelial cells (SEC) may manifest as
sinusoidal dilation, SOS, centrilobular perisinusoidal
and venular fibrosis, NRH, or peliosis, in increasing
order of severity (Figure 6).
s inusoidal dilation and sinusoidal
obstruction syndrome
The spectrum of sinusoidal damage associated with OX
is more complex than simple sinusoidal dilation,
already reported in many series,17 and includes eryth-
rocyte extravasation in the perisinusoidal space and
hepatocytic plate disruption, both signs of loss of
sinusoidal wall integrity. OX-related sinusoidal lesions
are morphologically similar to those of the so called
veno-occlusive disease (VOD), a condition described as
a complication of high-dose chemotherapy associated
Oxaliplatin-sinusoidal lesions frequent, partially prevented by bevacizumab 435
 2010 The Authors. Journal compilation  2010 Blackwell Publishing Ltd, Histopathology, 56, 430–439.
with stem cell transplantation. VOD was recently
renamed by DeLeve et al.21,23 as sinusoidal obstruction
syndrome (SOS), a term that we prefer as animal
models have demonstrated that centrilobular vein
involvement is not essential to the development of
SOS and that the main injury occurs at the level of the
hepatic sinusoids. Indeed, occlusion of the centrilobular
veins occurs only in 50–75% of patients with SOS after
haematopoietic stem cell transplantation.24
We would like to stress that SOS is not specific for
OX-related damage: several other drugs have been
associated with SOS at conventional doses.21,25 The
common feature for each compound is that they are
selectively more toxic for SEC than for hepatocytes.
morphological changes other than
sinusoidal
A further point highlighted by the present study is that
OX-related damage is associated with centrilobular
perisinusoidal and venular fibrosis, peliosis and NRH,
lesions that are morphologically distinct from sinusoi-
dal changes, although they are related to its severity.
NRH is characterized by the diffuse transformation of
normal hepatic parenchyma into small, regenerative
nodules, compressing the surrounding parenchyma
that exhibit atrophic plates or dilated sinusoids. NRH
may have a prolonged silent clinical course. When
symptomatic, patients develop cholestasis with elevated
alkaline phosphatases and ⁄ or signs of portal hyperten-
sion that may dominate the presentation and course of
disease.26 Despite today’s sensitive imaging modali-
ties,27 histology is the only way to diagnose NRH with
confidence. From a pathologist’s perspective, the diag-
nosis of NRH can be challenging and reticulin staining
is mandatory.28
Large autopsy series have established the prevalence
of NRH at 2.5%19 and its association with various
conditions, including chemotherapeutic agents.22,29 In
our series, the first investigating the prevalence of NRH
Table 2. Pathological
features
Types of chemotherapy
None
n = 111 (%)
OX
n = 204 (%)
OX ⁄ Bevacizumab
n = 70 (%) P
No hepatic vascular lesion 110 (99) 46* (22.6) 25* (35.7) <0.05*
Sinusoidal lesions (SOS) 0 (0) 158 (77.4) 45 (64.3) <0.05
Grade 1 0 (0) 31 (15.2) 23 (32.9) <0.001
Grade 2–3 0 (0) 127 (62.2) 22 (31.4) <0.001
Peliosis
Absent 111 (100) 178 (87.4) 67 (95.7) <0.001
Present 0 (0) 26 (14.6) 3 (4.3)
Nodular transformation
Absent 111 (100) 74 (36.3) 42 (60) <0.001
Present 0 (0) 130 (63.7) 28 (40)
Grade 1 0 34 (16.7) 15 (21.4)
Grade 2 0 37 (18.1) 5 (7.2)
Grade 3 (NRH) 0 59 (28.9) 8 (11.4)
Centrilobular ⁄ venular fibrosis
Absent 111 (100) 98 (48) 48 (68.6) <0.05
Present 0 (0) 106 (52) 22 (31.4)
Steatosis
Absent 68 (61.2) 122 (59.8%) 43 (61.4%) NS
Present 43 (38.8) 82 (40.2%) 27 (38.6%)
OX, oxaliplatin; SOS, sinusoidal obstruction syndrome; NRH, nodular regenerative hyperplasia.
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in a large number of patients treated with –OX, NRH
was present in 33% patients and was related to the
severity of sinusoidal injury. From a practical point of
view it is important to diagnose NRH because it is
associated with portal hypertension at the end of OX-
based chemotherapy13–15 and, in our experience, with
more difficult surgery.10
The pathogenesis of NRH has not yet been conclu-
sively established.26,29 It is believed to be related to
changes of intrahepatic blood flow, leading to atrophic
hypoperfused areas intermingled with hyperperfused
regenerative areas. Today, it is believed that the
circulatory impairment can start either as obstructive
portal vein injury19,20 or at the level of the sinu-
soids.21,26,30 Drugs associated with NRHare not asso-
ciated with portal vein lesions, as illustrated by the
present study. In NRH related to primary biliary
cirrhosis31,32 and in inactivation of Notch1 in mice,33
NRH develops in the absence of portal vein lesions.
Portal pressure measurements highlight the impor-
tance of the sinusoidal level of obstruction in NRH.34,35
It could be argued that portal vein embolization plays a
role in the pathogenesis of NRH. In large series of
patients who had undergone portal vein emboliza-
tion,36–40 and in our own experience,4,5,10 we did not
see portal vein embolization or ligation as contributing
to NRH. Cases of OX-related NRH without portal vein
embolization as well as on liver biopsy specimens on
the opposite side from embolized segments have been
reported.15
In the present series, centrilobular vein injury as well
as centrilobular fibrosis were proportionally associated
with the severity of sinusoidal lesions. It is unclear
whether this is because the more severe toxic injury
concerns more SEC or because involvement of the
centrilobular vein adds to the severity of the circulatory
disruption. In an animal model, mild fibrosis occurred
as a late SOS event, in relation to activation of hepatic
stellate cells (HSC). HSC activation has been reported in
patients with SOS.11,21,41
protective effect of bevacizumab
A third major finding of our study is that bevacizumab
reduced the severity of SOS as well as decreased the
incidence of peliosis, NRH and centrilobular fibrosis.
Notably, the role of VEGF in SOS has been studied
experimentally and offers some basis for the patholog-
ical findings. In the monocrotaline rat animal model of
SOS, matrix metalloproteinase (MMP-2 and MMP-9)
activation plays a major role in perisinusoidal matrix
degradation and participates in sinusoidal dilation.
VEGF induces MMP-9 expression by SEC.42 Thus, VEGF
blockade by bevacizumab may lead to down-regulation
of MMP-9 and possibly attenuates sinusoidal lesions.
The current study showing a decrease in OX-associated
hepatic lesions in patients treated by bevacizumab is
consistent with the above-mentioned findings.6 How-
ever, further studies are needed to understand the effects
of bevacizumab on oxaliplatin-associated liver injury.
From a clinician’s perspective, the importance of
OX-related hepatic injury has been highlighted essen-
tially with regard to the preoperative, operative or early
postoperative period,12–17 and we recently demon-
strated the effect of SOS on hepatic haemodynamics
and the delay of liver regeneration after major hepa-
tectomy in an experimental animal model.43 A
practical question therefore is whether SOS and NRH
are reversible once the cause has stopped, and in what
time frame. In the short term, we observed the
persistence and even the progression of SOS and NRH
in the setting of two-stage hepatectomies,10 suggesting
that there is no advantage in delaying an operation
that is otherwise well timed in terms of tumour
response to chemotherapy. In the long term, the issue
is more open: analogy with the settings of toxic oil
syndrome, in which NRH and portal hypertension were
noted 2.5 years after consuming the oil44 azathioprine
and 6-thioguanine, suggests that the changes are not
reversible; and we observed persistent SOS, NRH and
even fibrosis several months after chemotherapy had
Sinusoidal dilatation
NRH
SOS
Centrilobular 
fibrosis
Peliosis
Figure 6. Toxic liver injury induced by oxaliplatin (OX) may manifest
as sinusoidal dilatation, sinusoidal obstruction syndrome (SOS),
peliosis or nodular regenerative hyperplasia (NRH).
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been interrupted in some patients undergoing repeat
hepatectomies for recurrence.11 However, we have
recently operated on patients in whom severe
OX-related changes present at the first operation had
reverted to normal at the second hepatectomy. It is
certain that the risk of progressive disease is important,
particularly for patients who receive multiple cycles of
adjuvant or maintenance chemotherapy, and in
whom, despite an apparent indolent course, delayed
complications may develop.
the study from a multidisc ipl inary
perspective
Finally, this study, by stressing the frequency of
OX-associated lesions and the feasibility of objective
grading, has shown that the role of pathologists is
changing, from being limited to the appreciation of
resection margins in CRLM surgical resection, to a full
member of the multidisciplinary team. Data on non-
neoplastic liver and chemotherapy-associated lesions
are crucial to the therapeutic strategy; similarly, data
on tumour regression grade and tumour regrowth are
helpful to guide further surgery or chemotherapy, and
pathologists should be questioned accordingly.45–47
In conclusion, OX-associated liver changes will be
increasingly encountered in patients with CRLM both
because of the efficacy of this drug and because of the
prolonged survival offered by modern multidisciplinary
management. While the mechanisms of the changes
and possible preventive strategies, such as the associ-
ated use of bevacizumab, are being investigated,
pathologists should be aware that the distinctive
vascular lesions are common and their severity could
alter the management strategy and surgical risks.
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